Tpoxx Dosage
Generic name: tecovirimat
Dosage form: capsules and injection
Medically reviewed by A Ras MD.
Recommended Adult Dosing
Dosage forms: CAP: 200 mg; INJ: various
Restricted Distribution in US
Special Note, Monkeypox
- [FDA expanded access investigational new drug (EA-IND)]
- Info: for monkeypox in pts w/ suspected or confirmed infection w/ severe dz or aberrant infection or at high risk for severe dz; for monkeypox post-exposure prophylaxis considered on an individual case-by-case basis in consultation w/ CDC; not FDA approved for monkeypox; avail. from Strategic National Stockpile, contact local health department or CDC (770-488-7100 or poxvirus@cdc.gov)
- [mandatory reporting for EA-IND]
- Info: serious adverse events must be reported to CDC (regaffairs@cdc.gov) using the FDA MedWatch Form (www.fda.gov/medwatch/report.htm)
Smallpox
- [40-119 kg]
- Dose: 600 mg PO bid x14 days; Info: give w/in 30min after full moderate-high fat meal
- [>120 kg]
- Dose: 600 mg PO tid x14 days; Info: give w/in 30min after full moderate-high fat meal
Monkeypox
- [PO form, 40-119 kg]
- Dose: 600 mg PO bid x14 days; Info: for pts w/ severe dz or aberrant infection, or at high risk for severe dz per FDA EA-IND; may extend duration up to 90 days based on clinical response; give w/in 30min after full moderate-high fat meal
- [PO form, >120 kg]
- Dose: 600 mg PO tid x14 days; Info: for pts w/ severe dz or aberrant infection, or at high risk for severe dz per FDA EA-IND; may extend duration up to 90 days based on clinical response; give w/in 30min after full moderate-high fat meal
- [IV form, 35-119 kg]
- Dose: 200 mg IV q12h x14 days; Info: for pts w/ severe dz or aberrant infection, or at high risk for severe dz per FDA EA-IND; switch to PO regimen ASAP to complete course; may extend duration up to 90 days based on clinical response
- [IV form, >120 kg]
- Dose: 300 mg IV q12h x14 days; Info: for pts w/ severe dz or aberrant infection, or at high risk for severe dz per FDA EA-IND; switch to PO regimen ASAP to complete course; may extend duration up to 90 days based on clinical response
Renal dosing
- [PO route]
- renal impairment: no adjustment
- HD/PD: no adjustment; no supplement
- [IV route]
- CrCl >80: no adjustment; CrCl 30-80: not defined, caution advised; CrCl <30: contraindicated; Info: PO route preferred due to accumulation of toxic IV vehicle
- HD/PD: contraindicated
Hepatic dosing
- [no adjustment]
SRC: NLM .